We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

69 hedge funds and large institutions have $334M invested in Revance Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 32 increasing their positions, 14 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

129% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 14

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

11% more capital invested

Capital invested by funds: $301M → $334M (+$32.8M)

14% less funds holding

Funds holding: 80 → 69 (-11)

48% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 23

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $46K

Holders
69
Holders Change
-11
Holders Change %
-13.75%
% of All Funds
1.84%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
12
Increased
32
Reduced
14
Closed
23
Calls
–
Puts
$46K
Net Calls
-$46K
Net Calls Change
-$46K

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$23.9M
2
VAM
Visium Asset Management
New York
+$17.5M
3
Bank of New York Mellon
Bank of New York Mellon
New York
+$16.4M
4
PC
Polar Capital
United Kingdom
+$7.29M
5
BFA
BlackRock Fund Advisors
California
+$5.48M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$19.9M
2
CWAM
Columbia Wanger Asset Management
Illinois
-$10.9M
3
RIM
RS Investment Management
California
-$8.15M
4
PHS
PFM Health Sciences
California
-$7.51M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$5.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
Principal Financial Group
26
Principal Financial Group
Iowa
$1.23M -$3.11K -178 -0.2%
UBS AM
27
UBS AM
Illinois
$1.1M – – –
Geode Capital Management
28
Geode Capital Management
Massachusetts
$1.1M +$31K +1,773 +3%
WSA
29
Wall Street Associates
California
$971K – – –
Citadel Advisors
30
Citadel Advisors
Florida
$846K +$392K +22,420 +81%
SI
31
Standard Investments
New York
$811K – – –
BAMCO Inc
32
BAMCO Inc
New York
$728K – – –
CCI
33
Columbus Circle Investors
$644K -$310K -17,723 -32%
CS
34
Credit Suisse
Switzerland
$633K +$331K +18,935 +103%
B
35
Baird
Wisconsin
$556K -$56.7K -3,246 -9%
TCIM
36
TIAA CREF Investment Management
New York
$498K +$9.1K +521 +2%
BIM
37
BlackRock Investment Management
Delaware
$450K +$3.88K +222 +0.8%
State of New Jersey Common Pension Fund D
38
State of New Jersey Common Pension Fund D
New Jersey
$440K – – –
Charles Schwab
39
Charles Schwab
California
$427K +$103K +5,918 +31%
CPH
40
C Partners Holding
Switzerland
$407K +$419K +24,000 New
NA
41
Nottingham Advisors
New York
$390K +$402K +23,018 New
NFA
42
Nationwide Fund Advisors
Ohio
$314K -$10.3K -591 -3%
TI
43
Trexquant Investment
Connecticut
$301K +$311K +17,800 New
ProShare Advisors
44
ProShare Advisors
Maryland
$297K +$306K +17,544 New
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$270K +$1.19K +68 +0.4%
Swiss National Bank
46
Swiss National Bank
Switzerland
$219K +$41.9K +2,400 +23%
Arrowstreet Capital
47
Arrowstreet Capital
Massachusetts
$206K +$212K +12,161 New
TC
48
TFS Capital
Pennsylvania
$190K -$56K -3,204 -22%
TA
49
Teachers Advisors
New York
$178K – – –
Citigroup
50
Citigroup
New York
$133K +$132K +7,540 +2,513%
1
2
3 4

RVNC Hedge Fund Activity: Q4 2014 in Review

69 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2014, worth a combined $334M — up 11% from $301M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of RVNC and 12 opened new positions — a net loss of 11 holders — while 14 trimmed existing stakes and 32 added.

The largest buyer was Franklin Resources, adding an estimated $23.9M. The largest seller was Fidelity Investments, exiting entirely with an estimated $19.9M sold.

  • 69 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2014, down from 80 in Q3 2014.
  • Funds reported $334M of Revance Therapeutics, Inc. stock for Q4 2014, up 11% quarter-over-quarter.
  • 12 funds opened new Revance Therapeutics, Inc. positions in Q4 2014 and 23 closed out, a net change of -11 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q4 2014 was Franklin Resources, an estimated $23.9M added.
  • The largest Revance Therapeutics, Inc. seller in Q4 2014 was Fidelity Investments, an estimated $19.9M sold.

Based on aggregated 13F filings for Q4 2014.